Agomelatine is 'n melatonergiese antidepressant wat deur die farmaseutiese maatskappy Servier ontwikkel is. Dit word bemark vir die behandeling van ernstige depressiewe versteuring en daar is gerapporteer dat dit nie stakingsindroom veroorsaak nie en geen seksuele newe-effekte het in vergelyking met SSRI's nie, SNRI's en die ouer trisikliese antidepressante. Agomelatine kan ook positiewe uitwerking op slaap hê.
Agomelatine is a new antidepressant with selective agonist actions at melatonin receptors and selective antagonist action at serotonin 5HT-2C receptors.
Agomelatine can help regulate your'body clock' (circadian rhythm) with positive benefits on mood and sleepin depression Agomelatine is used in the treatment of depression or to help prevent depression returning, and isonly available with a doctor's prescription. The symptoms of depression vary from one person toanother, but commonly include persistent sadness, loss of interest in favourite activities, feelings of worthlessness, sleep problems, feeling of being slowed down, feelings of anxiety or changes in appetite and weight. Changes in your daily sleep and appetite patterns are examples of disturbances of your body clock that occur commonly indepression.
Agomelatine is 'n melatoninergiese agonis en selektiewe antagonis van 5-HT2C-reseptore, en daar is getoon dat dit aktief is in verskeie dieremodelle van depressie. Agomelatine (S20098) vertoon pKi waardes van 6.4 en 6.2 by inboorling (vark) en gekloon, mens (h)5-hidroksitriptamien (5-HT)2C reseptore, onderskeidelik.
